We’ve sliced and diced our portfolio into distinct “trends” that define our edge.
We are pleased to report that as of April 2021 the SOSV Climate Tech 100 have raised $1.85 billion from investors and have a market cap of $5.65 billion. The average company is four years old. SOSV (our parent fund) has invested $89 million in these companies and was in most cases the first investor, though we continued investing through early rounds.
IndieBio has never been one to shy away from the riskiest and most impactful investments for our planet. In fact, we embrace them.
Boosting female representation in the startup world is an ongoing challenge, but we’re dedicated to gender balance, not only because it’s the right thing to do, but because we would be dismissing impressive companies otherwise. We’ve found that more gender balance leads to better workplace culture and better ideas being exchanged.
Future of Food
It’s not just that we can make meat and fish in the lab, or with mushrooms and chickpeas. It’s not just that AI can predict the best plant ingredients to make the best tasting milk and yogurt. And it’s not just that yeast can be fermented to produce the healthier and better food preservatives. We’re diving deep every day into the foods that will satisfy novelty-seekers and conventionalists alike.
We’re putting big bets on the newest technologies and trends we think are ahead of the curve.
Future of Medicine
Medicine ain’t what it used to be. Today, bloodletting, skull-drilling and giving children cocaine for toothaches are relics of the past. Tomorrow, so too will addictive opioids, chemotherapy, and psychiatric drugs that are non-selectively bathing our bodies in chemicals.
The future of medicine is an exciting one, and we’re excited to share the most exciting technologies that enable the next wave of medicine and healthcare.
Our mission has always been Human and Planetary Health from the beginning, so it’s hard to say which of our companies are “impact” companies (in some ways, they all are).
Here, we narrowed down the startups that are directly addressing sustainability issues, improving public health, mitigating inequality, and democratizing access to infrastructure and technologies.
Every season of the year, a new batch and about one-sixth of our alumni are in raise mode. These companies are currently raising and would love to talk to interested investors. We can set up those meetings or you can contact the companies directly.
Drug development costs over $2 billion per drug with a failure rate of 90% because in vitro methods do not mimic the systemic organization of the human body and animal models are too different from Humans. As a result, the limitations of in vitro testing reduce the probability to develop safe and efficient drugs for patients needing them and […]
A new wave of RNA therapeutics has the potential to transform treatment for solid tumours. Existing non-viral technologies cannot target tumour cells. Moreover, these fail to release the therapeutic RNA into the cytosol, less than 1% leaks out of the endosomes (a sub-cellular compartment). The remaining 99% is degraded. EndoPore is Vitarka Therapeutics’ solution to […]
Period pain has an immediate negative impact on the quality of life, forcing 41% of menstruators to miss work or school. For places like the US, this results in over $7B loss annually. Current treatment options such as painkillers (NSAIDs), hormones, opioids, and surgery have serious side effects like kidney failure, stomach ulcers, blood clots, strokes, […]
To reach the full potential of RNA therapeutics, we have to understand how the tuning of just 4 ingredients in the delivery vehicle (lipid nanoparticles) can confer transfection and targeting efficiency. Dandelion is the first to leverage machine learning and biophysics in a systematic attempt to make sense of the chaos between LNP structure and […]
Many incurable health problems are characterized by the death of cells that cannot regenerate or repair themselves upon damage or injury. Cell therapy employs stem cells to produce functional cells transplanted into patients to treat and potentially reverse the damage. The access to cell therapies has been limited by the manufacturing challenges for allogeneic transplants […]